# Kure Cells

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kure-cells

- Industry: Biotechnology
- Headquarters: US
- Website: kurecells.bio
- Total disclosed funding: $10M
- Latest round: Series A (Oct 12, 2025)
- Investors on record: 4

## About

Kure Cells Inc., based in the US, specializes in pioneering cell therapy solutions that enhance clinical outcomes for hematological malignancies through innovative manufacturing processes.Kure Cells Inc. is focused on developing advanced cell therapy solutions, particularly through its Ultra-Fast (UF) CAR-T platform. Founded in 2021, the company is headquartered in the United States. In October 2025, Kure Cells raised USD 10 mn in PRE-SERIES A funding, led by Saudi Aramco Entrepreneurship Ventures, with participation from NantBioScience, Inc and Qomel Co. The total amount raised by the company is USD 10 mn from one notable funding round.Kure Cells specializes in innovative cell therapy solutions, particularly through its proprietary Ultra-Fast (UF) CAR-T platform. This platform significantly enhances the manufacturing process of CAR-T therapies, reducing production time from several weeks to less than 24 hours while maintaining the critical attributes of T-cell stemness and therapeutic potency. The UF CAR-T platform focuses on treating hematological malignancies such as CD19-relapsed or refractory non-Hodgkin lymphoma and BCMA-relapsed or refractory multiple myeloma, exhibiting an impressive 88% complete remission rate in clinical trials. Kure Cells targets a broad geographical market that includes the United States, Europe, the Middle East, India, and Latin America, engaging clinical centers and strategic partners in these regions to facilitate rapid manufacturing and trial operations.Kure Cells operates a business model that emphasizes partnerships and collaborations with clinical centers and strategic organizations to advance its cell therapy products. The company engages in B2B transactions, predominantly involving clinical trial operations and the commercialization of its CAR-T therapies. Revenue generation may involve arrangements for clinical trial support, manufacturing services, and agreements with healthcare providers to deliver its advanced therapies. Flagship products, such as the UF-kure19, are involved in structured pricing models that align with the therapeutic value delivered to healthcare institutions and patients. Specific transaction structures emphasize the company's commitment to making CAR-T therapies more accessible through streamlined production capabilities, fostering a profitable ecosystem that benefits both Kure Cells and its partners.In October 2025, Kure Cells plans to utilize the USD 10 mn raised in PRE-SERIES A funding to scale its cell therapy manufacturing capabilities and advance the clinical development of its pipeline. The company aims to introduce new products designed to further enhance treatment options for hematological malignancies. Furthermore, Kure Cells is focusing on expanding its market reach into new regions, including Asia and additional parts of Europe, by 2026.

## Funding rounds

- Series A, Oct 12, 2025, $10M — Saudi Aramco Entrepreneurship Ventures, Qomel Co., NantBio, Komel Healthcare

## Investors

- Saudi Aramco Entrepreneurship Ventures (https://capitalatlas.ai/funds/saudi-aramco-entrepreneurship-ventures) — Series A
- Qomel Co. — Series A
- NantBio — Series A
- Komel Healthcare — Series A